Therapeutic inhibition of USP7 promotes antitumor immune responses
Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012287
DOI: 10.1136/jitc-2025-012287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.09.2025. Verfasst von Angelika Muchowicz und 21 weiteren Autor:innen. Beteiligte Einrichtung: Molecure SA, Warsaw, Poland a.muchowicz@molecure.com. Hauptthemen laut MEDLINE: Ubiquitin-Specific Peptidase 7. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union in the framework of European Funds Smart Growth and European Regional Development Fund..
Abstract (Originalsprache)
Background
Ubiquitin-specific peptidase 7 (USP7) is a deubiquitinating enzyme that removes ubiquitin from specific protein substrates to modify their degradation rates thereby regulating crucial cellular processes integral to cancer. Conspicuously, overexpression of USP7 is strongly associated with the progression and poor prognosis in various cancers. Therefore, the design of potent and selective USP7 inhibitors poses an attractive therapeutic approach. The mechanism of action of USP7 inhibitors in cancer cells relies on MDM2 depletion and the restoration of p53.
Methods
In this study, we present OAT-4828, a novel and highly potent USP7-selective lead compound with a pharmacokinetic profile suitable for an oral administration. In in vivo models of melanoma and colon cancers, we determine the antitumor activity of OAT-4828, revealing its significant influence on various immune cell populations by flow cytometry.
Results
We provide evidence that OAT-4828 alters the tumor microenvironment, affecting immune cells including T cells, macrophages, and dendritic cells. As a result, OAT-4828 enhances antitumor functions, specifically improves T-cell activity, manifested by increased cytotoxicity, which is crucial for the effectiveness of OAT-4828 in vivo. Moreover, OAT-4828 changes the phenotype of macrophages and dendritic cells by decreasing the level of immunosuppressive proteins, such as programmed death-ligand 1. Translational results from the human co-culture system revealed the unexpected anti-angiogenic effect of the USP7 inhibitor, which was not observed when compared with an MDM2 inhibitor.
Conclusions
Overall, OAT-4828 demonstrates significant anticancer efficacy in melanoma and colon cancer models by activating the immune system, suggesting that USP7 may function as a checkpoint contributing to immunosuppression in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecure SA, Warsaw, Poland a.muchowicz@molecure.com.
- Laboratory of Cellular and Genetic Therapies, Center for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
- Molecure SA, Warsaw, Poland.
- Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Lesser Poland Voivodeship, Poland.
- Doctoral School, Medical University of Warsaw, Warsaw, Poland.
- Department of Bioinformatics, Polish Academy of Sciences, Warszawa, Poland.
Förderung
- European Union in the framework of European Funds Smart Growth and European Regional Development Fund.
Zitieren
APA
Muchowicz, A., Głuchowska, K. M., Grzybowski, M. M., Szostakowska-Rodzos, M., Rejczak, T., Belczyk-Ciesielska, A., Wilk, M. M., Kikulska, A., Marzeta-Assas, P., Zagozdzon, A., Pomper, P., Piwowar, K., Bryla, M., Wojciechowska, A., Chrzanowski, J., Nowicka, J., Gzik, A., Joachimiak, L., Koralewski, R., …, & Zasłona, Z. (2025). Therapeutic inhibition of USP7 promotes antitumor immune responses. Journal for ImmunoTherapy of Cancer, 13(9), e012287. https://doi.org/10.1136/jitc-2025-012287
Vancouver
Muchowicz A, Głuchowska KM, Grzybowski MM, Szostakowska-Rodzos M, Rejczak T, Belczyk-Ciesielska A, et al. Therapeutic inhibition of USP7 promotes antitumor immune responses. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012287. doi:10.1136/jitc-2025-012287
BibTeX
@article{Muchowicz2025,
author = {Muchowicz, Angelika and Głuchowska, Katarzyna M and Grzybowski, Marcin M and Szostakowska-Rodzos, Małgorzata and Rejczak, Tomasz and Belczyk-Ciesielska, Agnieszka and Wilk, Mieszko M and Kikulska, Agnieszka and Marzeta-Assas, Patrycja and Zagozdzon, Agnieszka and Pomper, Paulina and Piwowar, Katarzyna and Bryla, Marta and Wojciechowska, Alicja and Chrzanowski, Jacek and Nowicka, Julita and Gzik, Anna and Joachimiak, Lukasz and Koralewski, Robert and Błaszczyk, Roman and Zagozdzon, Radoslaw and Zasłona, Zbigniew},
title = {Therapeutic inhibition of USP7 promotes antitumor immune responses},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {9},
pages = {e012287},
doi = {10.1136/jitc-2025-012287}
}
EUVIMED